Healthcare Business

white pills

J.P. Morgan Very Positive on 3 Battered Specialty Pharmaceutical Stocks

Ever since the infamous Hillary Clinton tweet about pharmaceutical drug pricing, the biotech and specialty pharmaceutical stocks have taken a huge beating. In some cases, the markets have knocked valuations ...
Read Full Story »
graph

A Biotech and a Medical Device Stock, Each With Massive Upside Potential

Long-time aggressive investors know that biotechnology stocks can offer huge upside and also can get absolutely hammered, and in some cases even go out of business. Needless to say the ...
Read Full Story »
clinical trials

Why Nymox Pharmaceutical Took Off

Nymox Pharmaceutical Corp. (NASDAQ: NYMX) shares made solid headway in Wednesday’s session on positive results from a cancer trial. The company announced results from its seven-year prospective placebo controlled double-blind ...
Read Full Story »
Risk

Medgenics Announces Pricing of Secondary Offering

Medgenics Inc. (NYSEMKT: MDGN) saw its shares drop on Tuesday after the company announced the pricing of its secondary offering. The 3.64 million shares will be priced at $5.50 per ...
Read Full Story »
Pills and tablets

With Acquisitions, Will Impax Become the Next Great Generic Drug Seller?

Impax Laboratories Inc. (NASDAQ: IPXL) is about to step into a key role in the U.S. generic drug market. The company plans to take on a substantial portfolio of generic ...
Read Full Story »
blood cells

Global Blood Therapeutics Rises After Pricing Secondary Offering

Global Blood Therapeutics Inc. (NASDAQ: GBT) shares saw a handy gain in the premarket on Tuesday, despite the company pricing its secondary offering below its previous price level. This could be the ...
Read Full Story »
forest fire

4 Red-Hot Biotech Stocks With Over 100% Upside Potential

Long-time aggressive investors know that biotechnology stocks can offer huge upside and also can get absolutely hammered, and in some cases go out of business. Needless to say, the biotech ...
Read Full Story »
graph

Gilead Sciences Bounces on Preliminary Results

Shares of Gilead Sciences Inc. (NASDAQ: GILD) saw make a handy gain just off of their 52-week low following the release of preliminary data from its HIV treatment. After the stock dropped ...
Read Full Story »
IPO

Selecta Biosciences Closes in on IPO

Selecta Biosciences has registered an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) in regards to its initial public offering (IPO). The company intends to price its ...
Read Full Story »
DNA molecules

Syros Pharmaceuticals Announces Potential Pricing for IPO

Syros Pharmaceuticals has filed an S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). The company expects to price its 4 million shares ...
Read Full Story »
mosquito

How Inovio Pharma Is Joining the Fight Against the Zika Virus

Inovio Pharmaceuticals Inc. (NASDAQ: INO), in conjunction with GeneOne Life Science, is pioneering a new treatment for the Zika virus. In fact, early Monday morning the companies announced that they have ...
Read Full Story »
Female patient on gurney

Could This Be a Turning Point for Fate Therapeutics?

Shares of Fate Therapeutics Inc. (NASDAQ: FATE) saw a healthy gain early on Monday following a key U.S. Food and Drug Administration (FDA) approval. Looking at the stock performance in 2016, ...
Read Full Story »
IPO

Audentes Therapeutics Updates IPO Filing

Audentes Therapeutics filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). No pricing details were given in this filing, but ...
Read Full Story »
Pills and tablets

Paratek Makes Milestone Movement in Late-Stage Trial

Paratek Pharmaceuticals Inc. (NASDAQ: PRTK) saw its shares take a solid jump early on Friday after the results from its late-stage trial were released. The company announced that the Phase ...
Read Full Story »
Two Dollars

Tonix Pharmaceuticals Prices Secondary Offering

Shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) slid in Thursday’s session after the company announced the pricing of its secondary offering. It priced 5 million shares at $2, with an ...
Read Full Story »